NEWS

WIRES

OTHER

BioSante Shares on the Upswing While Cell Therapeutics Lag

The Paragon Report Provides Equity Research on BioSante Pharmaceuticals & Cell Therapeutics

Biotech stocks have been on an impressive run in 2012 -- handedly outperforming the Dow Jones industrial average year-to-date. The iShares Nasdaq Biotechnology Index Fund -- which contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals -- is up more than 16 percent this year. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on BioSante Pharmaceuticals Inc. (NASDAQ: BPAX) and Cell Therapeutics, Inc. (NASDAQ: CTIC). Access to the full company reports can be found at:

www.paragonreport.com/BPAX

www.paragonreport.com/CTIC

Earlier this month The Food and Drug Administration's (FDA) much anticipated guidelines for the sale of lower-cost versions of biotechnology drugs required studies showing that the generic copies are "highly similar" to the originals, but there are several ways that might be proven. According to market analysis firm Datamonitor, the worldwide market for copies of biotech medicines will grow to $3.7 billion by 2015, from just $243 million in 2010, as more than 30 branded biologics with sales of $51 billion lose patent exclusivity.

The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.

Cell Therapeutics is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. Shares of the company were hammered in late January after the company voluntarily withdrawn its New Drug Application for Pixuvri (pixantrone) for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma in patients who failed two or more lines of prior therapy. Shares of Cell Therapeutics are lagging the industry this year and are down more than 7 percent in 2012.

BioSante Pharmaceuticals, Inc., a specialty pharmaceutical company, develops products for female sexual health and oncology. Its lead products include LibiGel (transdermal testosterone gel) for the treatment of female sexual dysfunction. Earlier this month the company announced in a statement that the independent Data Monitoring Committee has completed the eighth unblinded review of the LibiGel Phase III cardiovascular and breast cancer safety study, which has completed enrollment of subjects. The independent DMC has recommended that the LibiGel safety study should continue as per the FDA-agreed protocol, without modifications. Shares of BPAX are up more than 50 percent year-to-date.

The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer